Following the success of CAR-T cell therapy in treating B cell hematologic malignancies, researchers are now exploring its application in AML, targeting antigens such as interleukin-3 receptor α (CD123), folate receptor beta (FRβ), CD33, Lewis Y, C-type lectin-like molecule-1 (CLL-1), NKG2D, and CD44v6 (42, 43). Here, CLEC12A is linked to acute myeloid leukemia.